Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status

Journal of Cancer Research and Therapeutics

Volumn 6, Issue 3, 2010, Pages 362-364

  Gupta, Ajay ^a   Raina, Vinod ^a   Garg, Priyam ^b   Kumar, Rakesh ^b  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Gefitinib; lung cancer; non smokers

Indexed keywords

CYTOKERATIN; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INDIA; LUNG ADENOCARCINOMA; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; THORAX RADIOGRAPHY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78650134534     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.73372     Document Type: Article

References (11)

1. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J. Geftinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: Results from a randomized, placebo controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
2. Ho C, Murray N, Laskin J, Melosky B, Anderson H, Bebb G. Asian ethnicity and adenocarcinoma histology continues to predict response to geftinib in patients treated for advanced non-small lung cancer of the lung in North America. Lung Cancer 2005;49:225-31.
3. Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, et al. Treatment of non-small-cell lung cancer and pharmacogenomics: Where we are and where we are going. Curr Opin Oncol 2006;18:135-43.
4. Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006;6:323-31.
5. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005;23:175-83.
6. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005;11:5878-85.
7. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005;16:1081-6.
8. Parikh P, Chang AY, Nag S, Digumarti R, Bhattacharyya GS, Doval DC, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol 2008;3:380-5.
9. Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
10. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
11. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.